D Ontaneda1, K Sakaie2, J Lin2, X-F Wang3, M J Lowe2, M D Phillips2, R J Fox4. 1. From the Department of Neurology (D.O., R.J.F.), Neurological Institute, Mellen Center for Multiple Sclerosis Treatment and Research ontaned@ccf.org. 2. Imaging Institute (K.S., J.L., M.J.L., M.D.P.). 3. Department of Quantitative Health Sciences (X.-F.W.), Cleveland Clinic Foundation, Cleveland, Ohio. 4. From the Department of Neurology (D.O., R.J.F.), Neurological Institute, Mellen Center for Multiple Sclerosis Treatment and Research.
Abstract
BACKGROUND AND PURPOSE: DTI is an MR imaging measure of brain tissue integrity. Little is known regarding the long-term longitudinal evolution of lesional and nonlesional tissue DTI parameters in multiple sclerosis and the present study examines DTI evolution over 4 years. MATERIALS AND METHODS: Twenty-one patients with multiple sclerosis were imaged for up to 48 months after starting natalizumab therapy. Gadolinium-enhancing lesions at baseline, chronic T2 lesions, and normal-appearing white matter were followed longitudinally. T2 lesions were subclassified as black holes and non-black holes. Within each ROI, the average values of DTI metrics were derived by using Analysis of Functional Neuro Images software. The longitudinal trend in DTI metrics was estimated by using a mixed-model regression analysis. RESULTS: A significant increase was observed for axial diffusivity (P < .001) in gadolinium-enhancing lesions and chronic T2 lesions during 4 years. No significant change in radial diffusivity either in normal-appearing white matter or lesional tissue was observed. The evolution of axial diffusivity was different in gadolinium-enhancing lesions (P < .001) and chronic T2 lesions (P = .02) compared with normal-appearing white matter. CONCLUSIONS: An increase in axial diffusion in both gadolinium-enhancing lesions and T2 lesions may relate to the complex evolution of chronically demyelinated brain tissue. Pathologic changes in normal-appearing white matter are likely more subtle than in lesional tissue and may explain the stability of these measures with DTI.
BACKGROUND AND PURPOSE: DTI is an MR imaging measure of brain tissue integrity. Little is known regarding the long-term longitudinal evolution of lesional and nonlesional tissue DTI parameters in multiple sclerosis and the present study examines DTI evolution over 4 years. MATERIALS AND METHODS: Twenty-one patients with multiple sclerosis were imaged for up to 48 months after starting natalizumab therapy. Gadolinium-enhancing lesions at baseline, chronic T2 lesions, and normal-appearing white matter were followed longitudinally. T2 lesions were subclassified as black holes and non-black holes. Within each ROI, the average values of DTI metrics were derived by using Analysis of Functional Neuro Images software. The longitudinal trend in DTI metrics was estimated by using a mixed-model regression analysis. RESULTS: A significant increase was observed for axial diffusivity (P < .001) in gadolinium-enhancing lesions and chronic T2 lesions during 4 years. No significant change in radial diffusivity either in normal-appearing white matter or lesional tissue was observed. The evolution of axial diffusivity was different in gadolinium-enhancing lesions (P < .001) and chronic T2 lesions (P = .02) compared with normal-appearing white matter. CONCLUSIONS: An increase in axial diffusion in both gadolinium-enhancing lesions and T2 lesions may relate to the complex evolution of chronically demyelinated brain tissue. Pathologic changes in normal-appearing white matter are likely more subtle than in lesional tissue and may explain the stability of these measures with DTI.
Authors: Natalia M Moll; Anna M Rietsch; Smitha Thomas; Amy J Ransohoff; Jar-Chi Lee; Robert Fox; Ansi Chang; Richard M Ransohoff; Elizabeth Fisher Journal: Ann Neurol Date: 2011-11 Impact factor: 10.422
Authors: David S Tuch; Timothy G Reese; Mette R Wiegell; Nikos Makris; John W Belliveau; Van J Wedeen Journal: Magn Reson Med Date: 2002-10 Impact factor: 4.668
Authors: Stephen M Smith; Mark Jenkinson; Mark W Woolrich; Christian F Beckmann; Timothy E J Behrens; Heidi Johansen-Berg; Peter R Bannister; Marilena De Luca; Ivana Drobnjak; David E Flitney; Rami K Niazy; James Saunders; John Vickers; Yongyue Zhang; Nicola De Stefano; J Michael Brady; Paul M Matthews Journal: Neuroimage Date: 2004 Impact factor: 6.556
Authors: D E Goodkin; W D Rooney; R Sloan; P Bacchetti; L Gee; M Vermathen; E Waubant; M Abundo; S Majumdar; S Nelson; M W Weiner Journal: Neurology Date: 1998-12 Impact factor: 9.910
Authors: Jaana Hiltunen; Riitta Hari; Veikko Jousmäki; Kiti Müller; Raimo Sepponen; Raimo Joensuu Journal: Neuroimage Date: 2006-05-06 Impact factor: 6.556
Authors: P A Brex; G J Parker; S M Leary; P D Molyneux; G J Barker; C A Davie; A J Thompson; D H Miller Journal: J Neurol Neurosurg Psychiatry Date: 2000-05 Impact factor: 10.154
Authors: Katline Metzger-Peter; Laurent Daniel Kremer; Gilles Edan; Paulo Loureiro De Sousa; Julien Lamy; Dominique Bagnard; Ayikoe-Guy Mensah-Nyagan; Thibault Tricard; Guillaume Mathey; Marc Debouverie; Eric Berger; Anne Kerbrat; Nicolas Meyer; Jérôme De Seze; Nicolas Collongues Journal: Trials Date: 2020-06-29 Impact factor: 2.279
Authors: Jenny Feng; Erik Offerman; Jian Lin; Elizabeth Fisher; Sarah M Planchon; Ken Sakaie; Mark Lowe; Kunio Nakamura; Jeffrey A Cohen; Daniel Ontaneda Journal: Mult Scler J Exp Transl Clin Date: 2019-06-14
Authors: Chenyu Wang; Michael H Barnett; Con Yiannikas; Joshua Barton; John Parratt; Yuyi You; Stuart L Graham; Alexander Klistorner Journal: Neurol Neuroimmunol Neuroinflamm Date: 2019-07-16
Authors: Chantel D Mayo; Laureen Harrison; Kristen Attwell-Pope; Lynneth Stuart-Hill; Jodie R Gawryluk Journal: Pilot Feasibility Stud Date: 2021-03-08